Table 2

Analysis of polymorphisms andlung cancer risk
Metabolic enzyme Gen SNP Genotype Cases Controls pa Unadjusted OR AdjustedbOR
n (%) n (%) [95% CI] [95% CI]
Phase I CYP1A1MspI T6235C T/T 608 (77.1) 632 (80.1) 0.203 Reference Reference
T/C 172 (21.8) 145 (18.4) 1.23 [0.96-1.58] 1.16 [0.87-1.53]
C/C 9 (1.1) 12 (1.5) 0.78 [0.33-1.86] 0.83 [0.31-2.20]
T/C + C/C 181 (22.9) 157 (19.9) 0.141 1.20 [0.94-1.53] 1.13 [0.86-1.49]
Phase II GSTM1 present/null present/present 375 (48.3) 358 (46.1) 0.387 Reference Reference
> = 1 null allele 401 (51.7) 418 (53.9) 0.92 [0.75-1.12] 0.95 [0.76-1.19]
Phase II GSTT1 present/null present/present 618 (79.6) 611 (78.7) 0.662 Reference Reference
> = 1 null allele 158 (20.4) 165 (21.3) 0.95 [0.74-1.21] 0.85 [0.64-1.12]
Phase II GSTP1 Ile105Val Ile/Ile 352 (44.7) 330 (41.9) 0.391 Reference Reference
Ile/Val 339 (43.0) 366 (46.4) 0.87 [0.70-1.07] 0.84 [0.66-1.06]
Val/Val 97 (12.3) 92 (11.7) 0.99 [0.72-1.36] 0.83 [0.57-1.19]
Ile/Val + Val/Val 436 (55.3) 458 (58.1) 0.263 0.89 [0.73-1.09] 0.83 [0.66-1.05]

a Chi-squared p-value.

b Adjusted by age, pack-years (non-smoker, <37PY, ≥37PY), family history of any cancer, and worker in list A occupation*.

* List A includes occupations known to be associated with lung cancer.

López-Cima et al.

López-Cima et al. BMC Cancer 2012 12:433   doi:10.1186/1471-2407-12-433

Open Data